With a market cap of$15.9 billion, International Flavors & Fragrances Inc. (IFF)is a global leader in creating flavors, fragrances, and specialty ingredients for food, beverage, beauty, and health industries. TheNew York-basedcompany operates through four main segments, Nourish, Scent, Health & Biosciences, and Pharma Solutions, serving customers worldwide.
The company is slated to announce its fiscalQ3 2025 earningsresults after the market closes on Tuesday, Nov. 4. Ahead of this event, analysts expect IFF to report anadjusted EPS of $1.03, a marginal decline from$1.04 in the year-ago quarter. It has exceeded Wall Street’s earnings expectations in three of the past four quarters while missing on another occasion.
-
Short Sellers Are Ganging Up on Beyond Meat Stock. Is There Hope for a Squeeze, or Should You Ditch BYND Now
-
If You Think AI’s A Bubble, You’re Already Late
-
With Nearly 500K Deliveries, Is Tesla Stock a Buy Before Q3 Earnings?
-
Our exclusive Barchart Brief newsletter is your FREE midday guide to what’s moving stocks, sectors, and investor sentiment – delivered right when you need the info most. Subscribe today!
For fiscal 2025, analysts forecast IFF to report adjusted EPS of $4.26, marking a decrease of 1.2% from$4.31 in fiscal 2024. However, adjusted EPS is expected to grow 6.3% year over year to $4.53 in fiscal 2026.
Over the past 52 weeks,shares ofIFF have dropped 40.8%, underperforming the broader S&P 500 Index’s ($SPX)13.5% gainand the Materials Select Sector SPDR Fund’s (XLB)9.3% declineover the same time frame.
On Aug. 5, IFF postedQ2 results with revenue of $2.8 billion and adjusted EPS of $1.15. However, thestock fell 6.3% the next day as investors reacted to underlying weakness. Its sales declined 4.3% year over year, adjusted EPS was down marginally, and adjusted EBITDA dropped 6.1% to $552 million, largely due to softer performance in the Scent segment.
Analysts’consensus view onIFFstockis cautiously optimistic, with a “Moderate Buy” rating overall. Among 20 analysts covering the stock, 12 suggest a “Strong Buy,” two give a “Moderate Buy,” and six recommend a “Hold.” The average analyst price target of $81.19 represents a premium of 29.7% from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originallypublished on Barchart.com
